Studienlage

Studien zu GLP-1-Agonisten (Semaglutid, Tirzepatid)

Automatisch aus PubMed geladen — gruppiert nach Outcome. Jeder Treffer verlinkt direkt zur Originalquelle.

11.744 Studien insgesamt·Stand: 4. Juni 2026Auf PubMed öffnen

Stoffwechsel · 4.760

Auf PubMed öffnen
  1. 01
    Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
    Horn DB, Ryan DH, Kis SG et al. · Lancet · 2026RCT
  2. 02
    Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case study
    Annemans L, Johansson E, Spaepen E et al. · J Med Econ · 2026
  3. 03
    Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial
    Johansson E, Wilding JPH, Upadhyay N et al. · J Med Econ · 2026
  4. 04
    GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers
    Chikatimalla R, Shah A, Shah T et al. · Ann Med · 2026
  5. 05
    Annual pharmacy cost per patient achieving composite treatment endpoints: a cost to target analysis of tirzepatide versus subcutaneous semaglutide 1 mg in patients with type 2 diabetes in the UK
    Kanumilli N, Osumili B, Evans J et al. · J Med Econ · 2026
  6. 06
    Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis
    Wang Y, Feng L, Wang Y et al. · Ren Fail · 2026
  7. 07
    Calculating cost per event avoided using a composite number needed to treat
    Toliver J, Wang J, Bhavsar J et al. · J Med Econ · 2026
  8. 08
    Depressed mood and suicidal thoughts reporting with GLP-1 receptor agonists in type 2 diabetes: A WHO VigiBase study
    Aboukaoud M, Hoch B, Weiser M et al. · J Affect Disord · 2026
  9. 09
    Short-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease
    Long W, Ningning L, Weijun H · Pak J Pharm Sci · 2026RCT
  10. 10
    Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review
    Gunasekaran P, Inban P, Agrawal A et al. · Dis Mon · 2026SR
  11. 11
    Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity
    Dong S, Xu Y, Gan R et al. · Med Res Rev · 2026
  12. 12
    Too much of a good thing
    Varghese D, Abdelsalam D, Ibrahim S et al. · Surv Ophthalmol · 2026
  13. 13
    [Value and benefit of basic insulin/GLP-1RA weekly preparation in clinical treatment of type 2 diabetes in adults]
    Zhang SC, Zang L, Cheng Y et al. · Zhonghua Yi Xue Za Zhi · 2026
  14. 14
    Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes
    Schwarz CR, Vilsbøll T, Aistrup MØ et al. · Pediatrics · 2026
  15. 15
    Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1
    Sattar N, Tchang BG, Vincent RP et al. · J Endocrinol Invest · 2026RCT
  16. 16
    Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular-kidney-metabolic stage progression: a real-world cohort study
    Wu JY, Lee KW, Huang SC et al. · Diabetes Res Clin Pract · 2026
  17. 17
    Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial
    Yamauchi T, Becker NP, Hagemann CA et al. · Lancet Diabetes Endocrinol · 2026RCT
  18. 18
    SemaGBA: A System Dynamics Model of the Semaglutide-Responsive Gut-Brain Axis A Model of How the Brain and Semaglutide Regulate Appetite and Weight
    Kennis VCW, van Riel NAW · Diabetes Obes Metab · 2026
  19. 19
    Oral semaglutide reduces diabetes-related distress in adults with type 2 diabetes mellitus switching from DPP-4 inhibitors. The DOORS prospective real-world Italian study
    Giaccari A, Borroni F, Dauriz M et al. · Diabetes Res Clin Pract · 2026
  20. 20
    Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study
    Maruyama F, Kitsunai H, Kitao N et al. · Diabetes Obes Metab · 2026
  21. 21
    Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial
    Bergenstal RM, Crandall JP, Rosin SP et al. · Diabetes Care · 2026RCT
  22. 22
    Five-year follow-up of incretin-based therapy in a patient with KCNJ11-related permanent neonatal diabetes: Achieving insulin discontinuation and sulfonylurea reduction
    Ohkuma T, Aotani R, Sakamoto W et al. · J Diabetes Investig · 2026
  23. 23
    Downstream Treatment Burden and Health-Care Utilization Following Initiation of GLP-1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes
    Alhamdan Y, Hsu JC, Lu CY · Diabetes Obes Metab · 2026
  24. 24
    Comparative efficacy and safety of three fixed-ratio combination products in type 2 diabetes: A network meta-analysis
    Wang X, Qin J, Liu Y et al. · J Diabetes Investig · 2026SR
  25. 25
    Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis
    Klein KR, Menacher A, Buse JB et al. · Diabetes Care · 2026

Herz-Kreislauf · 1.333

Auf PubMed öffnen
  1. 01
    GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers
    Chikatimalla R, Shah A, Shah T et al. · Ann Med · 2026
  2. 02
    Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis
    Wang Y, Feng L, Wang Y et al. · Ren Fail · 2026
  3. 03
    Calculating cost per event avoided using a composite number needed to treat
    Toliver J, Wang J, Bhavsar J et al. · J Med Econ · 2026
  4. 04
    Cost-effectiveness and budget-impact analysis of tirzepatide in heart failure with preserved ejection fraction and obesity in the German health-care system
    Estler B, Fröhlich H, Täger T et al. · Int J Cardiol · 2026
  5. 05
    Too much of a good thing
    Varghese D, Abdelsalam D, Ibrahim S et al. · Surv Ophthalmol · 2026
  6. 06
    Fat, muscle, and anti-obesity medications in cardiovascular disease prevention
    Khan MS, Dawood MH, Handelsman Y et al. · Eur Heart J · 2026
  7. 07
    Comparative effectiveness of tirzepatide versus GLP-1 receptor agonists on cardiovascular-kidney-metabolic stage progression: a real-world cohort study
    Wu JY, Lee KW, Huang SC et al. · Diabetes Res Clin Pract · 2026
  8. 08
    GLP-1-based therapies and limb outcomes in PAD: a systematic review and meta-analysis of real-world studies
    Boccatonda A, D'Ardes D, Brighenti A et al. · Diabetes Res Clin Pract · 2026SR
  9. 09
    R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25
    Arora P, Ramagopalan SV · J Comp Eff Res · 2026
  10. 10
    Childhood obesity and cardiac risk in youth: Emerging challenges toward 2050
    Mishra NK · Clin Nutr ESPEN · 2026
  11. 11
    Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis
    Klein KR, Menacher A, Buse JB et al. · Diabetes Care · 2026
  12. 12
    Real-World Cardiovascular Outcomes of Obesity Treatment With Tirzepatide Versus Semaglutide in Non-Diabetic Adults
    Katsura M, Horiuchi Y, Tanabe K et al. · Diabetes Obes Metab · 2026
  13. 13
    Lower Risk of Cardiovascular Events in Patients With Clinical Atherosclerotic Cardiovascular Disease Who Initiated Semaglutide 2.4 mg in the Real-World: Results From the SCORE-Clinical ASCVD Study
    Nanna MG, Mena-Hurtado C, Divino V et al. · Diabetes Obes Metab · 2026
  14. 14
    Clinical Management of Weight Regain and Cardiometabolic Consequences After Discontinuation of GLP-1 Receptor Agonists
    Shah E, AlShiab R, Abdo A et al. · Diabetes Obes Metab · 2026
  15. 15
    Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis
    Sebastian SA, Ayyalu T, Bimal T et al. · Dis Mon · 2026SR
  16. 16
    Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study
    Mortada I, Lee AW, Quach V et al. · Am J Cardiol · 2026
  17. 17
    Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis
    Pham TP, Vo TM, Nguyen TA et al. · Diabetes Obes Metab · 2026Meta
  18. 18
    Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis
    Abdelaal A, Abu Serhan H, Alsaadi M et al. · Ophthalmology · 2026SR
  19. 19
    Glucagon-like peptide-1 receptor agonist therapy is associated with improved outcomes of arteriovenous fistulae
    Hsu J, Ho B, Sayed R et al. · J Vasc Surg · 2026
  20. 20
    Tirzepatide and Reduced Risk of Diabetic Retinopathy and Related Complications: A Multicenter US Cohort Study
    Shah J, Razavi P, Festok M et al. · Ophthalmology · 2026
  21. 21
    Superior Cerebrovascular Outcomes with Tirzepatide versus Semaglutide in Diabetic CABG Patients: A Global Network Study of Propensity-Matched Patients
    Chunduri S, Bidaoui G, Hussein MH et al. · Cardiovasc Drugs Ther · 2026
  22. 22
    Vascular remodelling in a mouse model of heart failure with preserved ejection fraction
    Sanhueza-Olivares F, Valenzuela-Arce F, Calle-Chalco X et al. · J Physiol · 2026
  23. 23
    Insights into semaglutide cardiovascular research: Mechanisms, trials, and frontiers
    Zhang J, Gao G, He M et al. · Eur J Pharmacol · 2026
  24. 24
    Glucagon-like Peptide-1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy: Systematic Review and Meta-Analysis
    Dhivagaran T, Butt F, Arunasalam L et al. · Neurology · 2026SR
  25. 25
    Prevalence and Clinical Characteristics of Patients With Heart Failure With Preserved Ejection Fraction Who Meet the Obesity-Related Eligibility Criteria for Subcutaneous Incretin Receptor Agonists in Japan　- Insights From the PARACLETE Study
    Nishikawa K, Suzuki S, Minamisawa M et al. · Circ J · 2026